Area stenosis associated with non-invasive fractional flow reserve obtained from coronary CT images

Author(s):  
Jun-Mei Zhang ◽  
Tong Luo ◽  
Yunlong Huo ◽  
Min Wan ◽  
Terrance Chua ◽  
...  
PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0153070 ◽  
Author(s):  
Jun-Mei Zhang ◽  
Liang Zhong ◽  
Tong Luo ◽  
Aileen Mae Lomarda ◽  
Yunlong Huo ◽  
...  

2021 ◽  
Vol 15 ◽  
Author(s):  
Lavanya Cherukuri ◽  
Divya Birudaraju ◽  
Matthew J Budoff

Coronary artery disease (CAD) patients may have an obstructive disease on invasive coronary angiography, but few of these patients have had flow-limiting obstructive disease diagnosed on invasive fractional flow reserve (FFR). FFR is infrequently performed because of its cost- and time-effectiveness. Advancement in non-invasive imaging has enabled FFR to be derived non-invasively using coronary CT angiography (CCTA), without the need for induction of hyperemia or modification of the standard CCTA acquisition protocol. FFR derived from CCTA (FFRCT) has been shown to have excellent correlation with invasive FFR, and remains an effective diagnostic tool in the presence of reduced signal-to-noise ratio, coronary calcification and motion artifact. The utility of FFRCT has also helped to deepen our understanding of hemodynamically significant CAD. Hence, there is now interest in exploring the possible interplay between these mechanistic forces and their effect on the development of coronary plaque and the vulnerability of these plaques.


2016 ◽  
Vol 11 (1) ◽  
pp. 17
Author(s):  
Shah R Mohdnazri ◽  
◽  
◽  
◽  
Thomas R Keeble ◽  
...  

Fractional flow reserve (FFR) has been shown to improve outcomes when used to guide percutaneous coronary intervention (PCI). There have been two proposed cut-off points for FFR. The first was derived by comparing FFR against a series of non-invasive tests, with a value of ≤0.75 shown to predict a positive ischaemia test. It was then shown in the DEFER study that a vessel FFR value of ≥0.75 was associated with safe deferral of PCI. During the validation phase, a ‘grey zone’ for FFR values of between 0.76 and 0.80 was demonstrated, where a positive non-invasive test may still occur, but sensitivity and specificity were sub-optimal. Clinical judgement was therefore advised for values in this range. The FAME studies then moved the FFR cut-off point to ≤0.80, with a view to predicting outcomes. The ≤0.80 cut-off point has been adopted into clinical practice guidelines, whereas the lower value of ≤0.75 is no longer widely used. Here, the authors discuss the data underpinning these cut-off values and the practical implications for their use when using FFR guidance in PCI.


2021 ◽  
Vol 138 ◽  
pp. 109633
Author(s):  
Andreas M. Fischer ◽  
Marly van Assen ◽  
U. Joseph Schoepf ◽  
Andrew J. Matuskowitz ◽  
Akos Varga-Szemes ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document